BridgeBio Pharma, Inc.
(NASDAQ:BBIO)
$32.52
-1.09 (-3.24%)
Open: 1:13 PM
BBIO Stock Price Graph
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- YTD
- All
BBIO Stock Price Today
BridgeBio Pharma, Inc. (BBIO) stock declined over -3.24% intraday to trade at $32.52 a share on NASDAQ. The stock opened with a loss of -25.08% at $25.18 and touched an intraday high of $25.44, falling -3.24% against the last close of $33.61. The BridgeBio Pharma, Inc. in stock market went to a low of $24.39 during the session.
BBIO Stock Snapshot
$33.61
Prev. Close
5.66 Billion
Market Cap
$24.39
Day Low
$25.18
Open
N/A
Number of Shares
$25.44
Day High
N/A
P/E ratio
-3.91
EPS (TTM)
3.12
Cash Flow per Share
N/A
Free Float in %
-6.93
Book Value
1234870.00
Volume
BBIO Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|
Contact Details
Company Information
EmployeesN/A
Beta0.99
Sales or Revenue$9.43 Million
5Y Sales Change135.37%
Fiscal Year EndsDec. 2022
SectorHealthcare
IndustryBiotechnology
About Company
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
Peers
Frequently Asked Questions
What is the current BridgeBio Pharma, Inc. (BBIO) stock price?
BridgeBio Pharma, Inc. (NASDAQ: BBIO) stock price is $32.52 in the last trading session. During the trading session, BBIO stock reached the peak price of $25.44 while $24.39 was the lowest point it dropped to. The percentage change in BBIO stock occurred in the recent session was -3.24% while the dollar amount for the price change in BBIO stock was -$1.09.
BBIO's industry and sector of operation?
The NASDAQ listed BBIO is part of Biotechnology industry that operates in the broader Healthcare sector. BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases.
Who are the executives of BBIO?
Dr. Neil Kumar Ph.D.
Co-Founder, Pres, Chief Executive Officer & Director
Dr. Brian C. Stephenson C.F.A., Ph.D.
Chief Financial Officer, Sec. & Principal Accounting Officer
Dr. Richard H. Scheller Ph.D.
Chairman of R&D and Director
Dr. Brian C. Stephenson C.F.A., Ph.D.
CFO, Sec. & Principal Accounting Officer
How BBIO did perform over past 52-week?
BBIO's closing price is 1.71% higher than its 52-week low of $6.64 where as its distance from 52-week high of $36.36 is -0.32%.
How many employees does BBIO have?
Number of BBIO employees currently stands at N/A. BBIO operates from 421 Kipling Street, Palo Alto, CA 94301, US.
Link for BBIO official website?
Official Website of BBIO is: https://www.bridgebio.com
How do I contact BBIO?
BBIO could be contacted at phone #650 391 9740 and can also be accessed through its website. BBIO operates from 421 Kipling Street, Palo Alto, CA 94301, US.
How many shares of BBIO are traded daily?
BBIO stock volume for the day was 1234870.00 shares. The average number of BBIO shares traded daily for last 3 months was 1.43 Million.
What is the market cap of BBIO currently?
The market value of BBIO currently stands at $5.66 Billion with its latest stock price at $32.52 and N/A of its shares outstanding.